Share This Page
Drug Price Trends for NDC 52536-0880
✉ Email this page to a colleague
Average Pharmacy Cost for 52536-0880
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VERAPAMIL SR 120 MG CAPSULE | 52536-0880-01 | 1.06445 | EACH | 2025-04-23 |
| VERAPAMIL SR 120 MG CAPSULE | 52536-0880-01 | 1.08525 | EACH | 2025-03-19 |
| VERAPAMIL SR 120 MG CAPSULE | 52536-0880-01 | 1.10363 | EACH | 2025-03-12 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 52536-0880
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| No data available in table | |||||||
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Verapamil Hydrochloride (NDC 52536-0880)
Verapamil Hydrochloride, marketed under NDC 52536-0880 by Wilshire Pharmaceuticals, is a calcium channel blocker primarily used to treat hypertension, angina, and arrhythmias[7][11]. This analysis synthesizes market trends, pricing dynamics, and growth projections for this drug, leveraging data from industry reports, pricing databases, and competitive assessments.
Global Market Overview of Verapamil Hydrochloride
Current Market Valuation and Growth Trends
The global Verapamil Hydrochloride market was valued at $100 billion in 2023 and is projected to reach $140.71 billion by 2031, growing at a compound annual growth rate (CAGR) of 5%[11]. This growth is driven by the rising prevalence of cardiovascular diseases, particularly hypertension and angina, which affect over 1.3 billion adults worldwide[11][16]. The aging population and increased focus on managing chronic conditions further amplify demand, with North America and Europe accounting for the largest market shares due to advanced healthcare infrastructure and high diagnosis rates[11][17].
Regional Market Dynamics
- North America: Dominates the market, driven by high hypertension rates and robust generic drug production. The U.S. alone contributes over 40% of global sales[11][16].
- Asia-Pacific: Expected to witness the fastest growth (CAGR 6.2%) due to improving healthcare access and rising awareness of cardiovascular health[17].
- Europe: Stable growth supported by government initiatives to reduce cardiovascular mortality and increased adoption of cost-effective generics[9][16].
Pricing Analysis and Cost Trends
Current Price Benchmarks
Verapamil Hydrochloride pricing varies by formulation and distribution channel:
- Intravenous solution (2.5 mg/mL): Costs approximately $18 for 2 milliliters, with bulk purchasing reducing the unit price to $3.61–$8.88 per milliliter[10].
- Oral tablets (120 mg): Retail at $34.39 for 90 tablets, while extended-release formulations range from $23.02 to $52.17 per 90–100 tablets[10][15].
- Generic vs. Branded: Generic versions, including NDC 52536-0880, are 30–50% cheaper than branded alternatives like Verelan, making them preferred in cost-sensitive markets[10][16].
Factors Influencing Pricing
- Patent Expirations: Loss of exclusivity for branded drugs has intensified generic competition, pressuring prices downward[3][16].
- Manufacturing Costs: Innovations in drug delivery systems, such as extended-release formulations, marginally increase production costs but enhance market differentiation[11][16].
- Reimbursement Policies: Insurance coverage and government programs in the U.S. and EU ensure affordability, though out-of-pocket costs remain a barrier in developing regions[10][15].
Competitive Landscape and Key Players
Market Share Distribution
The market is fragmented, with key players including:
- Wilshire Pharmaceuticals: Leading supplier of generic Verapamil Hydrochloride, including NDC 52536-0880, leveraging cost-effective production[7][17].
- Pfizer and AbbVie: Focus on branded formulations and combination therapies (e.g., Trandolapril/Verapamil), though their market share is declining due to generics[15][16].
- Sun Pharmaceutical and Teva: Expanding generics portfolios in emerging markets, targeting price-sensitive regions[9][17].
Strategic Initiatives
- Product Differentiation: Companies invest in extended-release and combination therapies to extend patent life and justify premium pricing[11][15].
- Geographic Expansion: Partnerships with local distributors in Asia-Pacific and Africa aim to capture underserved populations[16][17].
Growth Drivers and Market Opportunities
Key Drivers
- Epidemiological Shifts: Cardiovascular diseases account for 32% of global deaths, necessitating long-term management with drugs like Verapamil[11][16].
- Aging Demographics: Individuals over 65 are 3x more likely to require antihypertensives, sustaining demand[11].
- Generic Penetration: Low-cost generics dominate 70% of the market, enhancing accessibility in developing economies[16][17].
Emerging Opportunities
- Innovative Formulations: Development of transdermal patches and bioequivalent injectables could capture niche segments[16].
- Telemedicine Integration: Digital health platforms improve prescription adherence, particularly in rural areas[17].
Challenges and Restraints
Market Barriers
- Price Erosion: Generic competition reduces profit margins, discouraging R&D investment[3][16].
- Regulatory Hurdles: Stringent bioequivalence standards delay generic approvals in regions like the EU[9][17].
- Supply Chain Disruptions: API shortages during the COVID-19 pandemic highlighted vulnerabilities in production logistics[11].
Affordability Concerns
In low-income countries, 40% of patients cannot afford chronic medication, limiting market expansion despite high disease burden[16][17].
Future Price Projections and Market Outlook
Short-Term Forecast (2025–2027)
Prices for generic Verapamil Hydrochloride are expected to decline by 2–4% annually due to increased competition, while branded variants may see 1–3% price hikes to offset R&D costs[10][15]. The U.S. market will remain stable, with Medicare negotiating lower bulk purchasing rates[10].
Long-Term Projections (2028–2033)
By 2031, the global market will surpass $140 billion, driven by Asia-Pacific’s growth. Prices for oral tablets may stabilize at $0.20–$0.30 per unit for generics, while novel formulations could command premiums up to $5.00 per dose[11][16].
Conclusion
Verapamil Hydrochloride (NDC 52536-0880) occupies a critical niche in cardiovascular care, with its generic status ensuring broad accessibility. While pricing pressures persist, strategic investments in innovation and emerging markets will sustain growth. Stakeholders must balance cost containment with quality improvements to capitalize on the projected 5% CAGR and address unmet needs in global healthcare[11][16].
"The future of the Verapamil market lies in balancing affordability with advanced therapeutic options." — Market Research Intellect Analysis, 2025[11]
Key Takeaways
- Verapamil Hydrochloride’s market will grow to $140.71 billion by 2031 at a 5% CAGR.
- Generic dominance and price erosion shape competitive strategies.
- Aging populations and cardiovascular disease prevalence underpin long-term demand.
FAQs
- What is Verapamil Hydrochloride used for?
It treats hypertension, angina, and arrhythmias by relaxing blood vessels[7][11]. - Why are generic versions cheaper?
Patent expirations allow multiple manufacturers to produce cost-equivalent alternatives[3][16]. - Which regions drive market growth?
North America leads, but Asia-Pacific shows the highest growth potential[11][17]. - How do prices vary by formulation?
Intravenous solutions cost ~$18/2mL, while oral tablets range from $0.20–$0.50 per unit[10][15]. - What challenges affect market expansion?
Regulatory hurdles, supply chain issues, and affordability gaps in low-income countries[9][16].
References
- https://ndclist.com/ndc/52536-510
- https://www.globenewswire.com/news-release/2024/09/13/2945827/28124/en/7MM-Migraine-Drug-Market-Forecast-and-Analysis-to-2033-Focus-on-US-France-Germany-Italy-Spain-the-UK-and-Japan.html
- https://www.insights10.com/report/us-hiv-drugs-market-analysis/
- https://www.pharmacompass.com/ndc-52536-500-03
- https://www.ci.brookfield.wi.us/DocumentView.asp?DID=832
- https://www.drugpatentwatch.com/p/drug-price/drugname/SCOPOLAMINE
- https://www.findacode.com/ndc/drugs/Verapamil_Hydrochloride
- https://www.drugpatentwatch.com/p/drug-price/drugname/VALTOCO
- https://www.24marketreports.com/life-sciences/global-verapamil-2023-420
- https://www.drugs.com/price-guide/verapamil
- https://www.marketresearchintellect.com/product/global-verapamil-hydrochloride-market/
- https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9b5abbb-2952-44ce-8cbb-415d9be23df4
- https://www.drugpatentwatch.com/p/drug-price/drugname/IBUPROFEN
- https://db.cbg-meb.nl/pars/h29700.pdf
- https://www.drugs.com/price-guide/trandolapril-verapamil
- https://sites.google.com/view/realisticmarketresearch/home/realistic-market/verapamil-hydrochloride-market-by-application
- https://www.cognitivemarketresearch.com/verapamil-hydrochloride-market-report
- https://www.prophecymarketinsights.com/market_insight/Global-Verapamil-Hydrochloride-Market-By-2117
- https://www.costplusdrugs.com/medications/verapamil-hcl-er-200mg-capsule-extended-release-verelan-pm/
- https://www.costplusdrugs.com/medications/verapamil-hcl-er-360mg-capsule-extended-release-verelan/
More… ↓
